Uterine Corpus Endometrial Carcinoma Cell Models for Research

Uterine corpus endometrial carcinoma (UCEC) is the most common gynecologic malignancy in developed countries. According to the World Health Organization (WHO) GLOBOCAN 2020 data, there were approximately 417,000 new cases and 97,000 deaths worldwide, with incidence rates rising due to increasing obesity and aging populations. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database reports a 5-year relative survival of about 81% for localized disease, dropping to 68% for regional spread and 18% for distant metastasis. Key risk factors include unopposed estrogen exposure, obesity, diabetes, and Lynch syndrome (hereditary mismatch repair deficiency). Despite advances in surgery and adjuvant therapy, recurrent and metastatic disease remains challenging, with limited targeted options for high-grade tumors.

UCEC is an ideal model for studying hormone-driven carcinogenesis, genomic instability, and tumor heterogeneity. The Cancer Genome Atlas (TCGA) project classified UCEC into four molecular subtypes: POLE ultramutated, microsatellite instability hypermutated (MSI), copy-number low (endometrioid), and copy-number high (serous-like). These subtypes have distinct clinical outcomes and therapeutic vulnerabilities, making UCEC a paradigm for precision oncology. Open questions include the role of PTEN loss in early tumorigenesis, the interplay between PI3K/AKT and Wnt signaling, and mechanisms of resistance to immune checkpoint inhibitors. Public datasets such as TCGA and DepMap provide rich resources for hypothesis generation and validation.

UCEC develops through the accumulation of genetic and epigenetic alterations that drive uncontrolled proliferation and survival. The major pathways include:

1. PI3K/AKT/mTOR pathway: Activation via mutations in PIK3CA, PIK3R1, PTEN loss, or AKT1 amplification leads to increased cell growth and survival.

2. Wnt/β-catenin pathway: CTNNB1 exon 3 mutations or loss of APC result in nuclear β-catenin accumulation and transcriptional activation of MYC and cyclin D1.

3. Mismatch repair (MMR) pathway: Defects in MLH1, MSH2, MSH6, or PMS2 cause microsatellite instability and hypermutation, often associated with Lynch syndrome or MLH1 promoter hypermethylation.

4. p53 pathway: TP53 mutations are frequent in serous-like and high-grade tumors, leading to genomic instability and aggressive behavior.

These pathways are not mutually exclusive; crosstalk between PI3K and Wnt signaling is common, and co-occurring mutations are frequent.

Based on TCGA PanCancer Atlas and COSMIC (Catalogue of Somatic Mutations in Cancer) data, the following genes are frequently altered in UCEC:

The molecular landscape of UCEC involves complex signaling networks that drive tumor progression and therapeutic resistance. Key nodes include:

• • PI3K/AKT/mTOR axis: PTEN loss and PIK3CA mutations activate AKT, leading to mTORC1-mediated protein synthesis and cell cycle progression. Downstream effectors include S6K1 and 4E-BP1.
• • MAPK/ERK pathway: KRAS mutations and EGFR overexpression activate RAF/MEK/ERK signaling, promoting proliferation and survival.
• • Wnt/β-catenin signaling: CTNNB1 mutations or Wnt ligand overexpression lead to β-catenin nuclear translocation, activating TCF/LEF transcription factors and target genes like MYC and CCND1.
• • Cell cycle regulation: CCND1 amplification and CDKN2A loss disrupt G1/S checkpoint, while TP53 mutations impair DNA damage response.
• • Immune evasion: MSI-high tumors have high neoantigen load, but PD-L1 expression and regulatory T cell infiltration can suppress anti-tumor immunity.

These networks provide multiple targets for therapeutic intervention, including PI3K inhibitors, MEK inhibitors, and immune checkpoint blockers.

Established cell lines are essential tools for studying UCEC biology. The following table lists commonly used lines with their key mutations (based on COSMIC and DepMap):

Organoid models derived from patient tumors preserve the genetic heterogeneity and 3D architecture of the original tumor, making them valuable for drug testing and personalized medicine. They can be established from both primary and metastatic lesions and recapitulate the molecular subtypes of UCEC.

Animal models are critical for studying tumor progression, metastasis, and therapeutic response in vivo. Common models include:

• • Patient-derived xenografts (PDX): Implantation of patient tumor fragments into immunodeficient mice. PDX models retain the genetic and histologic features of the original tumor and are useful for drug efficacy testing.
• • Genetically engineered mouse models (GEMM): Conditional knockout of Pten and/or activation of Kras mutations in the uterine epithelium (e.g., using Cre-loxP systems) recapitulate endometrioid carcinoma. Examples include Pten loxP/loxP; Kras LSL-G12D mice.
• • Chemically induced models: Administration of carcinogens like N-methyl-N-nitrosourea (MNU) or estrogen plus progesterone imbalance can induce endometrial tumors in rodents.
• • Syngeneic models: Mouse cell lines (e.g., CT-1) implanted into immunocompetent mice allow study of the tumor immune microenvironment.

Each model has advantages and limitations; the choice depends on the research question.

CRISPR-based gene editing enables precise introduction of disease-relevant mutations into isogenic cell lines, providing powerful tools for functional studies. For UCEC, common models include:

• • TP53 knockout (TP53-/-) in endometrial cancer cell lines (e.g., HEC-1A or Ishikawa) to study p53 loss effects on proliferation and genomic instability.
• • KRAS G12D knock-in in PTEN-null cells to model co-occurring mutations and test combination therapies.
• • PTEN knockout in immortalized endometrial epithelial cells to study early tumorigenesis.
• • PIK3CA H1047R knock-in to activate PI3K signaling and evaluate sensitivity to PI3K inhibitors.
• • MMR gene knockout (e.g., MLH1-/-) to induce microsatellite instability and model hypermutated tumors.

These gene-edited cell models are commercially available from specialized providers and are sequence-verified to ensure specificity. They accelerate research by providing clean genetic backgrounds, enabling controlled experiments that are not possible with naturally occurring cell lines. Isogenic pairs (wild-type vs. edited) allow direct comparison of the impact of a single genetic alteration, reducing confounding factors. Such models are essential for target validation, drug screening, and mechanistic studies.

Gene-edited cells are used to validate the functional role of genes in UCEC. For example:

• • Knockout of PTEN in endometrial cells leads to increased AKT phosphorylation and cell proliferation, confirming its tumor suppressor role.
• • Knock-in of KRAS G12D in PTEN-null cells enhances MAPK signaling and promotes anchorage-independent growth, demonstrating cooperation between pathways.
• • Knockout of ARID1A in endometrial organoids results in altered chromatin accessibility and increased invasiveness, linking chromatin remodeling to metastasis.

These models allow researchers to dissect gene function in a controlled genetic background, complementing RNAi and overexpression studies.

Isogenic cell line pairs are invaluable for drug screening and resistance studies. For instance:

• • PTEN-null cells are more sensitive to PI3K inhibitors (e.g., alpelisib) compared to PTEN wild-type cells, validating the target.
• • KRAS G12D knock-in cells show resistance to EGFR inhibitors but sensitivity to MEK inhibitors, guiding combination strategies.
• • TP53 knockout cells exhibit increased resistance to DNA-damaging agents like cisplatin, mimicking clinical resistance in high-grade tumors.

By using isogenic pairs, researchers can identify drug-specific effects and mechanisms of resistance, leading to more effective therapeutic regimens.

CRISPR screens in UCEC cell lines can identify synthetic lethal interactions and novel biomarkers. For example:

• • A genome-wide CRISPR knockout screen in PTEN-null cells may reveal genes that are essential only in the absence of PTEN, such as ARID1A or CHD4, providing potential therapeutic targets.
• • CRISPR activation screens can identify genes that confer resistance to immune checkpoint inhibitors, such as PD-L1 regulators.
• • Gene-edited models can be used to validate candidate biomarkers by correlating genetic alterations with drug response or patient outcomes.

These approaches accelerate the discovery of predictive biomarkers and new drug targets.

Researchers can leverage public databases to integrate genomic, transcriptomic, and functional data for UCEC. The following table lists key resources: